ClinicalTrials.gov
ClinicalTrials.gov Menu

Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00192829
Recruitment Status : Unknown
Verified March 2007 by Rambam Health Care Campus.
Recruitment status was:  Recruiting
First Posted : September 19, 2005
Last Update Posted : April 11, 2007
Sponsor:
Information provided by:
Rambam Health Care Campus

Brief Summary:
The association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. The aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (NSCLC).

Condition or disease Intervention/treatment
Non-Small Cell Lung Carcinoma Venous Thromboembolism Procedure: Blood sample withdrawal

Study Type : Observational
Enrollment : 100 participants
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Hypercoagulable Parameters as Predictors of Thrombotic Events and Prognosis in Patients With Advanced Non-Small Cell Lung Carcinoma
Study Start Date : June 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of NSCLC.
  • normal serum bilirubin
  • informed concent to participate in the study

Exclusion Criteria:

  • anticoagulant therapy
  • infectious disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00192829


Contacts
Contact: Galit Sarig, Ph.D +972-4-8543503 g_sarig@rambam.health.gov.il
Contact: Nissim Haim, M.D

Locations
Israel
Hematology Laboratory Recruiting
Haifa, Israel
Contact: Galit Sarig, Ph.D    +972-4-8543523    g_sarig@rambam.health.gov.il   
Principal Investigator: Galit Sarig, Ph.D         
Oncology Institution, Rambam Health Campus Recruiting
Haifa, Israel
Contact: Nissim Haim, M.D       n_haim@rambam.health.gov.il   
Principal Investigator: Nissim Haim, M.D         
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Principal Investigator: Galit Sarig, Ph.D Rambam Health Care Campus

Publications:
ClinicalTrials.gov Identifier: NCT00192829     History of Changes
Other Study ID Numbers: Thrombosis and cancer.CTIL
First Posted: September 19, 2005    Key Record Dates
Last Update Posted: April 11, 2007
Last Verified: March 2007

Keywords provided by Rambam Health Care Campus:
Lung cancer
Thrombosis
Hypercoagulable

Additional relevant MeSH terms:
Carcinoma
Thromboembolism
Venous Thromboembolism
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Thrombophilia
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Hematologic Diseases